Jagpreet Chhatwal, MS, PhD, is the Director of the Center for Health Technology Assessment at Mass General Brigham and an Associate Professor at Harvard Medical School. He has co-authored over 140 research articles, and his work has been cited in leading media outlets, including NPR, Forbes, Wall Street Journal, and New York Times. His work has directly informed policy at the White House, the CDC, multiple state health departments, and the World Health Organization.

Dr. Chhatwal’s work sits at the intersection of decision science, artificial intelligence, and health economics. His research applies decision-analytic modeling and AI-based methods to inform clinical guidelines, health policy, and health technology assessment — translating complex analytical findings into insights for clinicians, payers, and policymakers.

Dr. Chhatwal received the inaugural 2025 ISPOR Impact Award, and 2026 John M. Eisenberg Award from the Society of Medical Decision Making, two prestigious recognitions honoring his multi-year contributions to hepatitis C elimination research in the United States.

He co-led the ISPOR Task Force on the use of Generative AI for systematic literature reviews, which produced influential guidance on the use of large language models for medical evidence synthesis.

His current research spans multiple disease areas, including hepatitis C, liver cancer, opioid and alcohol use disorder, mental health, esophageal cancer, and metabolic dysfunction-associated steatohepatitis (MASH).

Interactive Online Modeling Tools:

COVID-19 Simulator: The COVID-19 Simulator has a collection of tools to help health policymakers and practitioners make decisions regarding policy, and strategy related to coronavirus disease 2019.

Hep C State Policy Simulator: Developed in collaboration with the CDC, the Hep C State Policy Simulator helps state health policy makers and practitioners make decisions regarding policy, strategy, and investments related to hepatitis C.

Hep C Calculator: Developed in collaboration with the WHO, this interactive tool evaluates the cost-effectiveness of hepatitis C treatment and testing in different countries.

MASLD Simulator: The MASLD Simulator is an interactive, open-access tool that provides information on the short- and long-term risks associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.

Selected News:

STAT: Congress Can Eradicate Hepatitis C and Reduce the Deficit at the Same Time

The Harvard Gazette: Remember Opioid Crisis? It’s Gotten Worse

The Harvard Gazette: Tab for Liver Disease Tied to Drinking Projected to Double over 20 Years